Incyte Corp.

-0.23 (-0.35%)
Indices Changes, Regulatory, Earnings Announcements

Incyte Announces Full Results From Phase 3 True-V Program Evaluating Ruxolitinib Cream (Opzelura™) In Patients With Vitiligo

Published: 10/02/2021 09:30 GMT
Incyte Corp. (INCY) - Incyte Announces Full Results From Phase 3 True-v Program Evaluating Ruxolitinib Cream (opzelura™) in Patients With Vitiligo.
Incyte Corp- Treatment With Opzelura Resulted in Facial Repigmentation at Week 24, Characterized by Patients Achieving ≥75% Improvement From Baseline in Facial Vitiligo.
Incyte Corp - Significantly Greater Proportion of Patients Treated With Ruxolitinib Cream Also Achieved ≥50% Improvement From Baseline in Total Body Vitiligo Area Scoring Index.
Incyte Corp - Results Will Be Presented in a Late-breaking Oral Presentation at European Academy of Dermatology and Venereology (eadv) 30(th) Congress.
Incyte Corp - Treatment-emergent Adverse Events Were Consistent With Previous Studies, With No Serious Treatment-related Adverse Events Reported.
Revenue is expected to be $738.6 Million
Adjusted EPS is expected to be $0.58

Next Quarter Revenue Guidance is expected to be $795.48 Million
Next Quarter EPS Guidance is expected to be $0.59

More details on our Analysts Page.